Biocon Limited
20th KM, Hosur Road
Electronic City
Bangalore 560 100, India
T 91 80 2808 2808
F 91 80 2852 3423

CIN : L24234KA1978PLC003417

www.biocon.com

BIO/SECL/SG/2024-25/134

December 01, 2024

To The Manager, **BSE Limited** Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001	To The Manager, **National Stock Exchange of India Limited** Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050
Scrip Code - 532523	**Scrip Symbol - Biocon**

Dear Sir/Madam,

Subject: Notification to Stock Exchanges

Please find enclosed the company statement titled **"U.S.FDA Approves Biocon Biologics' YESINTEK™, Bmab 1200 biosimilar to J&J's Stelara® (Ustekinumab)".**

The above information will also be available on the website of the Company at www.biocon.com.

Kindly take the same on record and acknowledge.

Thanking You,

Yours faithfully,

For **Biocon Limited**

BIOCON LIMITED ★ BANGALORE ★

_____

Mayank Verma
Company Secretary & Compliance Officer
Membership No: ACS 18776

Encl: as above

NOTIFICATION TO STOCK EXCHANGE

COMPANY STATEMENT

U.S.FDA Approves Biocon Biologics' YESINTEK™, Bmab 1200 biosimilar to J&J's Stelara® (Ustekinumab)

Bengaluru, Karnataka, India, December 01, 2024

Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), announced today that the **U.S. Food and Drug Administration (FDA) has approved YESINTEK™** (*Ustekinumab-kfce*), a biosimilar to the reference product, Stelara® (*Ustekinumab*).

YESINTEK™, a monoclonal antibody, is approved for the treatment of Crohn's disease, Ulcerative Colitis, Plaque Psoriasis and Psoriatic Arthritis.

Biocon Biologics Ltd had previously notified the Stock Exchange on Feb 29, 2024, that the Company had entered into a settlement and licensing agreement with Janssen Biotech Inc., Janssen Sciences Ireland, and Johnson & Johnson (collectively known as Janssen) **to commercialize YESINTEK™ in the United States of America no later than on February 22, 2025, upon approval from the U.S. FDA.**

– Company Spokesperson

For more information: seema.ahuja@biocon.com